{"links":{"html":"https://www.erudio.com/reports/solara-nct06706076","json":"https://www.erudio.com/reports/solara-nct06706076.json","markdown":"https://www.erudio.com/reports/solara-nct06706076.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"solara-06706076"}},"request":"https://www.erudio.com/contact?report=solara-06706076"},"offer":{"cited_commentary_sources":23,"verified_hcp_statements":71,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":4,"optional":true,"price_per_verified_person_usd":15,"price_usd":60,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"solara-nct06706076"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=solara-06706076","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/solara-nct06706076","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-29T21:21:12.893427Z","notify_subscribers":false,"status":"corrected","summary":"The page names the trial's tested drugs (BH-30643; BH-30643 plus carboplatin plus pemetrexed)."},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":11,"no_commentary_found":2},"aspects":[{"claim_count":0,"coverage":"no_commentary_found","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":0,"title":"Primary endpoint: Dose-limiting toxicities (DLTs) (Phase 1, Dose Escalation)"},{"claim_count":0,"coverage":"no_commentary_found","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":0,"title":"Primary endpoint: Recommended Phase 2 dose (RP2D) (Phase 1, Dose Expansion/Optimization)"},{"claim_count":10,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.primaryOutcomes[2]","source_count":8,"title":"Primary endpoint: Objective Response Rate (ORR) (Phase 2)"},{"claim_count":7,"coverage":"discussed","id":"T4","registry_field":"outcomesModule.secondaryOutcomes","source_count":6,"title":"Secondary endpoints"},{"claim_count":14,"coverage":"discussed","id":"T5","registry_field":"conditionsModule","source_count":9,"title":"Population and setting"},{"claim_count":1,"coverage":"discussed","id":"T6","registry_field":"armsInterventionsModule.armGroups","source_count":1,"title":"The comparison"},{"claim_count":19,"coverage":"discussed","id":"T7","registry_field":"outcomesModule","source_count":9,"title":"Safety and tolerability"},{"claim_count":8,"coverage":"discussed","id":"T8","registry_field":"designModule","source_count":5,"title":"Design and conduct"},{"claim_count":12,"coverage":"discussed","id":"A1","source_count":8,"title":"Resistance coverage, mechanistic rationale and biomarker interpretation"},{"claim_count":13,"coverage":"discussed","id":"A2","source_count":4,"title":"Positioning against osimertinib and alternative regimens"},{"claim_count":5,"coverage":"discussed","id":"A3","source_count":6,"title":"CNS exposure and potential intracranial benefit"},{"claim_count":6,"coverage":"discussed","id":"A4","source_count":3,"title":"Trial access, patient support and unanswered questions"},{"claim_count":12,"coverage":"discussed","id":"A5","source_count":7,"title":"Durability, evolving datasets and regulatory-development expectations"}],"counts":{"cited_sources":23,"claims_by_expression_type":{"comparison":3,"interpretation":24,"opinion":18,"question":1,"restatement":9,"uncertainty":3,"unspecified":13},"claims_by_kind":{"source_observation":71},"clinician_statements":6,"evidence_units":40,"findings":7,"organisational_accounts":12,"people_cited":6,"people_identity_verified":4,"people_total":7,"screened_sources":88,"verified_claims":71},"findings_index":[{"id":"F1","structure":{"claims":14,"claims_by_group":{"comparisons":1,"experience":0,"questions":2,"restated":2,"views":9},"has_counterview":true,"limitations":2,"links":{"context":0,"support":15},"ma_question":true,"named_voices":5,"passages":8,"sources":5,"sources_by_kind":{"commentary":4,"media":1}},"title":"Acceptable liver monitoring is not the same as resolved hepatic risk"},{"id":"F2","structure":{"claims":10,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":3,"views":7},"has_counterview":true,"limitations":3,"links":{"context":0,"support":11},"ma_question":true,"named_voices":6,"passages":9,"sources":7,"sources_by_kind":{"commentary":6,"media":1}},"title":"Early response optimism remains qualified by durability, selection and the limits of an oral-option narrative"},{"id":"F3","structure":{"claims":8,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":1,"views":7},"has_counterview":true,"limitations":2,"links":{"context":0,"support":8},"ma_question":true,"named_voices":2,"passages":2,"sources":2,"sources_by_kind":{"commentary":2}},"title":"Proposed positioning is selective, not blanket replacement of osimertinib"},{"id":"F4","structure":{"claims":11,"claims_by_group":{"comparisons":2,"experience":0,"questions":1,"restated":1,"views":7},"has_counterview":true,"limitations":3,"links":{"context":0,"support":13},"ma_question":true,"named_voices":5,"passages":9,"sources":7,"sources_by_kind":{"commentary":5,"media":2}},"title":"Mutation breadth is valued because resistance can be heterogeneous"},{"id":"F5","structure":{"claims":6,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":6},"has_counterview":false,"limitations":2,"links":{"context":0,"support":6},"ma_question":true,"named_voices":3,"passages":4,"sources":4,"sources_by_kind":{"commentary":3,"media":1}},"title":"CNS exposure versus comparative intracranial benefit"},{"id":"F6","structure":{"claims":6,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":0,"views":5},"has_counterview":false,"limitations":2,"links":{"context":0,"support":6},"ma_question":true,"named_voices":2,"passages":3,"sources":3,"sources_by_kind":{"commentary":3}},"title":"Referral enthusiasm includes slot constraints and a patient-support role"},{"id":"F7","structure":{"claims":10,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":4,"views":5},"has_counterview":true,"limitations":3,"links":{"context":3,"support":12},"ma_question":true,"named_voices":3,"passages":9,"sources":6,"sources_by_kind":{"commentary":5,"media":1}},"title":"Development optimism should remain separate from regulatory certainty"}],"medical_affairs_question":"What durability, hepatic-event timing and subgroup-specific comparative evidence would make the proposed roles and monitoring burden clinically persuasive?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Hepatic risk: practical reassurance has explicit boundaries"},{"id":"section-2","level":2,"title":"Response estimates: population differences, durability and patient expectations"},{"id":"section-3","level":2,"title":"Treatment positioning: selective opportunity, not universal replacement"},{"id":"section-4","level":2,"title":"Resistance breadth: a specific heterogeneity rationale, not proven universal coverage"},{"id":"section-5","level":2,"title":"CNS evidence: exposure, shrinkage and comparative benefit"},{"id":"section-6","level":2,"title":"Access and patient support: enthusiasm is conditional on an actual opportunity"},{"id":"section-7","level":2,"title":"Development expectations: planned milestones and analyst assumptions are not outcomes"},{"id":"section-8","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, non randomized, single group, phase1, phase2","trial_dimensions":[{"findings":[],"id":"T1","label":"Primary endpoint: Dose-limiting toxicities (DLTs) (Phase 1, Dose Escalation)"},{"findings":[],"id":"T2","label":"Primary endpoint: Recommended Phase 2 dose (RP2D) (Phase 1, Dose Expansion/Optimization)"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":7},{"id":"F4","shared_claims":1},{"id":"F7","shared_claims":1}],"id":"T3","label":"Primary endpoint: Objective Response Rate (ORR) (Phase 2)"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":1},{"id":"F5","shared_claims":3}],"id":"T4","label":"Secondary endpoints"},{"findings":[{"id":"F2","shared_claims":3},{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":3},{"id":"F6","shared_claims":3}],"id":"T5","label":"Population and setting"},{"findings":[{"id":"F3","shared_claims":1},{"id":"F7","shared_claims":1}],"id":"T6","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":14},{"id":"F2","shared_claims":4},{"id":"F3","shared_claims":1},{"id":"F7","shared_claims":1}],"id":"T7","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":1},{"id":"F7","shared_claims":2}],"id":"T8","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-29T21:21:12.893427Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-29T21:38:17Z","record_hash":"1737b2752d635e38c3efa072fffc151aa6fd4b2889460f3e793237c3fc1189e5","release_hash":"392661c28eda3bb8f5e8c0cfd7b6ab8433811c1ba9e95e7d09d69147e57d0b50","report_id":"erudio-nct06706076","run_id":"84627076-4f8c-42a7-b103-3d7a7226573f","schema_version":"5.0","slug":"solara-06706076","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"Clinician commentary on SOLARA in the sources reviewed for this edition leads to one open question: What durability, hepatic-event timing and subgroup-specific comparative evidence would make the proposed roles and monitoring burden clinically persuasive? Its leading findings: (1) acceptable liver monitoring is not the same as resolved hepatic risk. (2) early response optimism remains qualified by durability, selection and the limits of an oral-option narrative. (3) proposed positioning is selective, not blanket replacement of osimertinib. 4 more findings follow. 88 sources screened, 23 cited; not all HCPs or all public discussion.","meta_description":"88 sources screened · 71 verified statements (6 from clinicians verified by NPI or staff page) from 23 sources · 7 findings. Updated Oct 29, 2026.","person_names_policy":"role_only","sample_findings":{"reason":"Sample findings are not shown for this edition.","status":"unavailable"}},"publication":{"approved_at":"2026-10-29T21:38:17Z","approved_by":"Erudio publisher","corrections":[{"affected_ids":[],"date":"2026-10-29T22:21:17Z","summary":"The page names the trial's tested drugs (BH-30643; BH-30643 plus carboplatin plus pemetrexed)."}],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":88},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","2 matching sources (2 X threads) could not be read and are not included.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","51 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits apply, so some matching discussion may be missing.","Thirty-four potentially relevant discussions that did not name the trial were not read, two sources could not be read, and multiple passages were not fully assessed. Absence of commentary in a topic should therefore not be interpreted as absence of clinician concern.","The material mixes clinician-attributed posts, sponsor statements, organizations, investment-oriented accounts and unidentified spoken commentary. Repeated announcements and reposts are not additional independently expressed clinical views.","Clinical roles are not established for several named authors. Professional identifiers and affiliations provide background only; they do not establish who spoke an unidentified passage or increase the weight of an opinion.","No full results publication or protocol document was available in the sources reviewed. No exact product label was identified for BH-30643 alone or with carboplatin/pemetrexed, so commentary cannot substitute for detailed methods, adjudicated safety information or regulatory documentation.","Response estimates and safety percentages refer to different data summaries, populations, doses and event categories. Their differences do not establish a temporal trend, contradiction or change of mind.","Several BH-30643 discussions never name SOLARA. They are included for their relevance to the same clinical decision and are identified by their stated setting, rather than treated as additional SOLARA analyses.","The episode gives inconsistent FDA-meeting dates. Neither date is selected as confirmed, and development plans, accelerated-approval aims and analyst success assumptions remain prospective."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":1,"linkedin_post":1,"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":19,"x_video":1,"youtube":0},"by_evidence_role":{"commentary":23},"count":23,"evidence_window":{"end":"2026-10-08","start":"2025-10-24"},"retrieval_snapshot":"2026-10-29T19:45:30.979654Z","timeline":[{"count":1,"week":"2025-W43"},{"count":1,"week":"2025-W44"},{"count":1,"week":"2025-W49"},{"count":3,"week":"2026-W23"},{"count":1,"week":"2026-W34"},{"count":2,"week":"2026-W36"},{"count":1,"week":"2026-W37"},{"count":8,"week":"2026-W38"},{"count":4,"week":"2026-W39"},{"count":1,"week":"2026-W40"},{"count":1,"week":"2026-W41"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT06706076:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT06706076:context","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-ffhfzwr3igtwt4y7zdompvjv-3mte2ssapv32t","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-t5kvjzece3qgysdmwvem36xv-3myjk5mkwh22s","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-vi44gwopaal4pvutdcbm257n-3myie6iigxu2y","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-zwaxkm7x44me7z7nwpagim42-3muoufqrq4f23","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7467696000346816512","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:7c4f86","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1882171733631016974:e9d3752d-64d9-4ada-9528-7efb1241dd12","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1882171928846442692:9339dc94-7a37-4f90-99bf-7144639f1cd1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1882179491335975351:725c7e62-2cfb-474e-9226-477f6145e6b8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1882180583608193193:3da730d5-9880-477f-a65c-e3d0d2403e97","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1882187055217959352:0c31f65c-0389-4d7d-8766-dea05d4de2b6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1882194672850010471:d363ad2b-a43c-4438-ba0d-85b930ebc45a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1882202193090232741:2f52340e-cb11-4762-a46e-a37c874228b1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1882209703729696806:63bd2091-8a2c-4ce7-8d23-3b10cd1e9496","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1882217299442376990:0e0e7c03-a0a6-4d68-b016-88f82ff8dc7b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1882224852612075856:fad7ed45-3090-4163-823f-d808fa4d15df","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1882232409065972181:a1dff465-408f-4484-9ae2-d665933ffe71","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1882239930090627236:a5cd9287-2d40-41a2-8c57-cc9cd986443f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1882247462137782293:15ae3d37-95e1-477e-82cb-a44e4d9fc973","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1882250078007775414:92bf29cf-89f3-41ce-a86d-3536fdfec960","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1882255041580654891:534e042d-03c1-4b0a-a967-c595b8f84b13","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1882526460352634924:b2a30407-0a55-4ca1-94cd-6f9f32359935","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1882554112614465798:322f4005-410a-4dc4-8bdb-3020a13ea2bd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1926683536888561907:ab2b2319-2e48-4e98-88f0-07022b481347","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929131818256609683:4cbd1383-d2fb-4d90-8846-2fd6d90f876e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1958861877036904808:e6f7f620-7a62-4272-b9ed-0ba9d10613af","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1978069440697655607:653953f3-7af6-4e3e-921e-0fdc81ea98dc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1981761056335695942:366464e1-1cfa-40a0-bc53-a39c6ea5040b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1982623461353877820:a498890b-f68d-4ed8-9325-2ac1e7a5804c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1983542527312712062:c789f001-86e7-4f11-a776-c4744306adc8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2017207963643978107:cd1fad5c-a737-4821-87cc-a5f617a4e3e6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2024895750287884569:4657e90d-f184-44b7-8f89-4ae6bc374d52","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2051270622332776554:b2528b7f-fd50-4edf-85e1-ff589636c131","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2057570292541657197:58352903-2389-4145-83eb-eb8c26790ee9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2058593876060102708:f0e1c83b-272f-4ccf-b9c2-94c7eb8e93e2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060382637886173415:ff328453-9d71-4de1-a08f-ec3cd8146c22","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061794115981816002:3d9f2c95-d906-424d-9fbb-475584f32462","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061835436352242049:1c3ec51e-ed38-4f96-bc75-f108eb32e0a3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061835872513741025:639826fe-1dfe-4376-9dfd-23fbea5c5054","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061842589750624729:a6bfc8d6-260f-415e-b286-250a056adc1c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061858215092969627:2c3fb11e-9253-4c1d-99e0-84eea8b5521d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2062501770723811718:34b7fad4-1aa7-43dd-a185-6a62af6b14da","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2062519750148698302:554b59b9-96b4-488b-8bd1-8c1ec347709d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2064694118719037910:5a478ce1-5566-44a4-ba3c-f31f1d080645","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2089719032815710471:3101b9ad-8123-45ae-9f36-5b82533fbcf6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2089726625193562370:8b10eb81-b31f-4bb9-a19b-f4ff629fa412","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2089759255654002815:64b1ef64-34a1-4c39-9b6d-621075415f73","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2089802740884971625:385d8679-7de2-4320-a2d9-bc8126856e39","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2090028730886369628:6438b6bf-5e6b-4d38-90cf-9a6c0fa417c6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2090107271200063748:e0e78300-48d0-4c1e-9d09-f8f12d0218a5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2094421281345241155:85c8df28-1ef3-4bf3-a380-191ccf71566d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2094742756694388761:7e977b99-fdba-476c-a1b2-70dd3e639e50","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2094770829783359861:a649a401-5283-4d65-9c08-67bcd0c13865","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2094788206525055153:5da02017-5677-4ff5-b3f6-f41eb06d966b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2094795393481724286:c04087f2-3fe0-40b4-b44a-b86fe28ceaa7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2095140180957036960:d43f5748-6bf7-43e1-91d1-dcf192904825","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2097726816731664777:ad305da9-c298-4edf-8cb4-c16b6e785255","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2097977836258935022:1f590137-9f65-4aaf-92d6-554d39cb6229","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2098736931328622608:362ae04e-7b2d-4caa-8658-51f16507f768","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099682614772904259:93b6283f-1a00-4602-bdc3-398d5beee827","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099818917653028890:943bd5a6-0e54-4041-8c02-bdd4dcbddf86","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099823305620328720:17054f2a-1577-4422-a835-1441cc9a4717","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099827017185431763:27e1b7e5-b909-4609-be73-9497fd1a8708","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099854040507064538:62cdefdc-05ce-4b94-9445-b34b6fa9f6d5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099861649406771314:7c842370-467d-4055-a71f-60cfcd1b1ea8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099867208474108151:a5268e86-d0ba-4cbc-9f0f-6c354127c75e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099878135676485970:a367657f-ff16-451f-9a73-c466983a0e77","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099981568383316271:52cc1d73-df8a-4668-aa74-7418d23cc247","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2100108978252365827:1253058a-5788-4113-a96d-db64122730b4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2100264771870421227:ba5ec967-0c69-44d3-9a87-388ebde11622","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2100557384368197994:a101df6c-85a4-4e02-865c-2aab721c0fdd","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2100584039014916371:7b54aff1-7453-47b1-92c8-6f0a0bc2d370","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2100909318086308238:ee67e901-3685-4b14-b714-e1aa87801441","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2100934276023730608:c00ab13a-c6a1-4996-a1d0-828f9d3cc6f8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2101054654268227935:0425e6c8-f425-4422-a517-2fb1f5ade7fc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2101431549367562441:644fa5a3-0be2-479c-9106-3d615e685106","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2101998018157244591:c82c2122-5cc5-4f8b-90ca-2cec4d8f1940","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102796867600023958:130aac0a-c615-43ce-8be0-402692fa71de","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103152844614349281:5d6f7d0f-bce2-405e-af22-13f5fd405ca6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103862535145599358:00818b4b-97ca-4a5d-908a-688f4a13e031","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2103896359438881049:352a6f7c-b3ca-45ac-94bf-7812fb61d662","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2105466727731712158:d9e1cf53-2944-4ac4-b9be-1734b4928356","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2108282563038978420:33c725b9-74c7-4f6c-8a91-b7abfb2aaf35","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113229424552198173:8bc378cb-8e58-41f0-b305-1e8c3b7bdf29","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113517254696448429:96e01b24-b682-421a-96dc-acbac793b389","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114392179212951939:9b52216e-4caa-47d1-affd-2547f5e29381","quote_policy":"short_quote_link_out"},{"id":"mcp:x_video:2100557384368197994","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:38LrSaW1Iyo","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":4,"linkedin_post":1,"other":0,"podcast":1,"publication":0,"registry":0,"regulatory":0,"x_thread":80,"x_video":1,"youtube":1},"by_evidence_role":{"commentary":88},"count":88,"evidence_window":{"end":"2026-10-25","start":"2025-01-22"},"retrieval_snapshot":"2026-10-29T19:45:30.979654Z","timeline":[{"count":17,"week":"2025-W04"},{"count":1,"week":"2025-W21"},{"count":1,"week":"2025-W22"},{"count":1,"week":"2025-W34"},{"count":1,"week":"2025-W42"},{"count":1,"week":"2025-W43"},{"count":2,"week":"2025-W44"},{"count":1,"week":"2025-W49"},{"count":1,"week":"2026-W05"},{"count":1,"week":"2026-W08"},{"count":1,"week":"2026-W19"},{"count":2,"week":"2026-W21"},{"count":1,"week":"2026-W22"},{"count":8,"week":"2026-W23"},{"count":1,"week":"2026-W24"},{"count":7,"week":"2026-W34"},{"count":7,"week":"2026-W36"},{"count":3,"week":"2026-W37"},{"count":18,"week":"2026-W38"},{"count":5,"week":"2026-W39"},{"count":2,"week":"2026-W40"},{"count":1,"week":"2026-W41"},{"count":1,"week":"2026-W42"},{"count":5,"week":"2026-W43"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: bh-30643","status":"unmapped"},{"reason":"Unmapped registry intervention: bh-30643 combo therapy with carboplatin/pemetrexed","status":"unmapped"}],"indications":[{"reason":"Unmapped registry condition: NSCLC (Advanced Non-small Cell Lung Cancer)","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":{"reason":"Conditions lack a therapeutic-area mapping.","status":"unmapped"}},"trial":{"acronym":"SOLARA","aliases":["SOLARA","A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations","A Phase 1/2 Open-Label, Multicenter, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BH-30643 in Adult Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations (SOLARA)"],"brief_title":"A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["NSCLC (Advanced Non-small Cell Lung Cancer)"],"display_interventions":[["BH-30643"],["BH-30643","carboplatin","pemetrexed"]],"enrollment":{"count":675,"type":"ESTIMATED"},"interventions":[{"name":"BH-30643","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"BH-30643 combo therapy with Carboplatin/Pemetrexed","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"BH-30643","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT06706076","official_title":"A Phase 1/2 Open-Label, Multicenter, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BH-30643 in Adult Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations (SOLARA)","overall_status":"RECRUITING","phase":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2029-01-31","type":"ESTIMATED"},"primary_endpoints":[{"description":"Assess dose-limiting toxicities (DLTs) as defined in the study protocol.","measure":"Dose-limiting toxicities (DLTs) (Phase 1, Dose Escalation)","timeFrame":"Within the first 21 days of the first dose of BH-30643."},{"description":"Determine the RP2D for Phase 2.","measure":"Recommended Phase 2 dose (RP2D) (Phase 1, Dose Expansion/Optimization)","timeFrame":"Within 21 days of last participant dosed during Dose Expansion/Optimization."},{"description":"Determine ORR as assessed by Blinded Independent Central Review (BICR).","measure":"Objective Response Rate (ORR) (Phase 2)","timeFrame":"Approximately 3 years after the first participant dosed."}],"registered_date":{"date":"2024-11-26","type":"ACTUAL"},"registry_last_updated":"2026-08-05","registry_url":"https://clinicaltrials.gov/study/NCT06706076","short_name":"SOLARA","short_name_basis":"registry_acronym","sponsor":"BlossomHill Therapeutics","start_date":{"date":"2025-01-09","type":"ACTUAL"},"study_design":"interventional, non randomized, single group, phase1, phase2","study_ids":[{"id":"BH-30643-01","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}